InflaRx (IFRX) Debt Ratio (2020 - 2022)

InflaRx's (IFRX) quarterly Debt Ratio came in at 0.0 in Q3 2022, up 13.4% quarter-over-quarter from 0.0 in Q2 2022.

InflaRx (IFRX) Debt Ratio (2020 - 2022) Analysis & Trends

InflaRx has disclosed Debt Ratio across 3 years of filings, most recently posting 0.0 for Q3 2022.

  • Debt Ratio for Q3 2022 came in at 0.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was 0.0 (changed N/A YoY), and the FY2021 annual result was 0.0, down 17.24% from the prior year.
  • Debt Ratio came in at 0.0 for Q3 2022 at InflaRx, up from 0.0 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.0 in Q1 2021 to a low of 0.0 in Q2 2021.
  • The 3-year median for Debt Ratio is 0.0 (2022), against an average of 0.0.
  • Peak annual rise in Debt Ratio reached 22.84% in 2022, while the deepest fall reached 53.08% in 2022.
  • InflaRx's Debt Ratio stood at 0.0 in 2020, then fell by 17.24% to 0.0 in 2021, then increased by 16.74% to 0.0 in 2022.
  • The last three Debt Ratio figures came in at 0.0 (Q3 2022), 0.0 (Q2 2022), and 0.0 (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.18
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 InflaRx 764.68 Mn 764.68 Mn 10,877.40 -

Historic Data

Download Data
DateValue
Sep 30, 2022 0.00
Jun 30, 2022 0.00
Mar 31, 2022 0.00
Dec 31, 2021 0.00
Jun 30, 2021 0.00
Mar 31, 2021 0.00
Dec 31, 2020 0.00